3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1/2
3
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Carcinoma, Renal Cell
2
Advanced Cancer
2
Unilateral Breast Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
pembrolizumab
23
Paclitaxel
20
Carboplatin
18
Taxes
7
temsirolimus
6
Trastuzumab
6
Topotecan
5
Radiotherapy
5
atezolizumab
4
Specimen Handling
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Gemcitabine
4
Docetaxel
4
Cisplatin
4
Biopsy
4
Bevacizumab
4
olaparib
3
lenvatinib
3
dostarlimab
3
Sirolimus
3
Pemetrexed
3
Irinotecan
3
Interleukin-12 Subunit p35
3
Fulvestrant
3
Cetuximab
3
Albumin-Bound Paclitaxel
3
spartalizumab
2
gedatolisib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Endometrial Neoplasms
×
abemaciclib
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled